Norway: Advocate General Opinion In The Astrazeneca Case Of Abuse Of Dominant Position (Case C-457/10 P): Appeal From AZ Should Be Dismissed – Mondaq

The generics companies alleged that AstraZeneca was preventing them from introducing generic versions of omeprazole on the market in several European countries. The complaint resulted in the 60 million Euro fine six years later.  The basis for the fine was twofold.

Leave a Reply

Your email address will not be published. Required fields are marked *

*